AgingPhase 1NCT07404449
Sex-Speciffic Longevity Food Supplements
A Phase 1 study testing compound food supplements - female specific and compound food supplements - male specific in people with Aging, run by University of Primorska at 1 site in Slovenia.
Trial summary
The use of food supplements with the aim of increasing longevity in the general population is rapidly increasing, while high-quality clinical evidence on the efficacy of comprehensive formulations and their impact on biomarkers of aging is lacking. Read more about this study
- Who is it for?
- Ages 50 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Aging
- What is being tested?
- compound food supplements - female specific and compound food supplements - male specific
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 1 siteSlovenia
- Study dates
- 7 Mar 2026to Mar 2027
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Body mass index (BMI) between 22 kg/m2 and 30 kg/m2
- Postmenopausal women (at least 12 months without menstruation)
- Healthy individuals, without risk of chronic non-communicable diseases
- Signed written informed consent
Who cannot join
- Acute and chronic diseases (cardiovascular diseases, diabetes, neurodegenerative diseases, gastrointestinal diseases)
- Patients with serious clinical conditions such as cancer, severe infections, severe psychiatric disorders, autoimmune diseases, inflammatory diseases
- BMI less than 22 kg/m2 and greater than 30 kg/m2
- Celiac disease or gluten intolerance
- Presence of implants, devices or other foreign materials in the measurement area
- Smoking
Show all 10Show fewer
- Atypical sleep patterns
- Use of dietary supplements and medications
- Extreme physical activity
- Excessive alcohol consumption (more than one drink per day for women, more than two drinks per day for men)
Trial locations and contacts
1 site in 1 country.
Slovenia1 site
University pf Primorska, Faculty of Health Sciences
Izola, 6310
About this study
Official title: Effects of Sex-Speciffic Compound Food Supplements on Changes in Biomarkers and Epigenetic Changes Associated With Longevity
The use of food supplements with the aim of increasing longevity in the general population is rapidly increasing, while high-quality clinical evidence on the efficacy of comprehensive formulations and their impact on biomarkers of aging is lacking. The investigators will perform a double-blind, placebo-controlled, randomized clinical trial of a selected sex-specific dietary supplement in relation to longevity in a selected population of healthy adults of both sexes between the ages of 50 and 70.
The main questions the study answers are:
Read more
Does the 6-month use of the longevity supplement impacts the 6-months change in different markers for measuring biological age compared to placebo?
The study will involve 60 subjects, of whom 30 will consume the sex-specific longevity food supplements and 30 will consume a placebo.
The study will last 6 months. The participants will visit the Faculty four times: at the beginning of the study (background measurement), after one, three and six months of consuming the dietary supplement or placebo.
At each visit, the participants will undergo anthropometric measurements, blood pressure measurements, and blood samples will be taken to determine baseline haematocrite, albumin, creatinine, alcaline phosphatase, lipid profile, glucose concentration, inflammatory parameters, antioxidant potential, inflammatory markers, liver enzymes, and expression of genes for autophagy and oxidative stress. The participants will also complete 3-day food diaries and questionnaires on general health, physical activity, and quality of sleep and life.
On baseline and final (six months) measurements resting metabolic rate, DXA body composition measurements will be performed and saliva samples will be obtained for DNA methilation determination.
- Conditions
- Aging
- Being tested
- compound food supplements - female specific, compound food supplements - male specific, Placebo
- Keywords
- biological age, food supplement, longevity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
compound food supplements - female specificDietary supplement
2 capsules per day at breakfast with glass of water for 6 months.
compound food supplements - male specificDietary supplement
2 capsules per day at breakfast with glass of water for 6 months.
PlaceboDietary supplement
2 capsules per day at breakfast with glass of water for 6 months.
| Study group | Role | What they receive |
|---|---|---|
| Female longevity food supplement | Experimental | 6-month daily consumption of 2 capsules of female food supplement in the morning. Receives: Dietary Supplement: compound food supplements - female specific |
| Female placebo | Placebo comparator | 6-month daily consumption of 2 capsules of maltodextrin in the morning. Receives: Dietary Supplement: Placebo |
| Male longevity food supplement | Experimental | 6-month daily consumption of 2 capsules of male food supplement in the morning. Receives: Dietary Supplement: compound food supplements - male specific |
| Male placebo | Placebo comparator | 6-month daily consumption of 2 capsules of maltodextrin in the morning. Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Albumin
Albumin levels will be measured from venous blood at baseline, after 1, 3 and 6 months of daily dietary supplements use.
Measured: From enrolment to the end of last measurement at 6 months.
Creatinine
Creatinine levels will be measured from venous blood at baseline, after 1, 3 and 6 months of daily dietary supplements use.
Measured: From enrolment to the end of last measurement at 6 months.
Glucose
Glucose levels will be measured from venous blood at baseline, after 1, 3 and 6 months of daily dietary supplements use.
Measured: From enrolment to the end of last measurement at 6 months.
CRP
CRP levels will be measured from venous blood at baseline, after 1, 3 and 6 months of daily dietary supplements use.
Measured: From enrolment to the end of last measurement at 6 months.
Lymphocyte percent
Lymphocyte percent will be measured from venous blood at baseline, after 1, 3 and 6 months of daily dietary supplements use.
Measured: From enrolment to the end of last measurement at 6 months.
Mean cell volume
Mean cell volume will be measured from venous blood at baseline, after 1, 3 and 6 months of daily dietary supplements use.
Measured: From enrolment to the end of last measurement at 6 months.
Red cell distribution width
Red cell distribution width will be measured from venous blood at baseline, after 1, 3 and 6 months of daily dietary supplements use.
Measured: From enrolment to the end of last measurement at 6 months.
Alcaline phosphatase
Alcaline phosphatase will be measured from venous blood at baseline, after 1, 3 and 6 months of daily dietary supplements use.
Measured: From enrolment to the end of last measurement at 6 months.
White blood cell count
White blood cell count will be measured from venous blood at baseline, after 1, 3 and 6 months of daily dietary supplements use.
Measured: From enrolment to the end of last measurement at 6 months.
PhenoAge
PhenoAge will be calculated from albumin, creatinine, glucose, lymphocyte percent, mean cell volume, red cell distribution width, alcaline phosphatase, white blood cell count and cronological age at baseline, after 1, 3 and 6 months of daily dietary supplements use (according to Ruan et al, 2023).
Measured: From enrolment to the end of last measurement at 6 months.
DNA methylation
DNA methylation will be measured from saliva at baseline and 6 months of daily dietary supplements use.
Measured: From enrolment to the end of last measurement at 6 months.
Horvath epigenetic age
Horvath epigenetic age will be determined from saliva DNA methylation data (according to Horvath \& Raj, 2018) at baseline and 6 months of daily dietary supplements use..
Measured: From enrolment to the end of last measurement at 6 months.
Secondary outcomes (18)
Total cholesterol
Total cholesterol levels will be measured from venous blood at baseline, after 1, 3 and 6 months of daily dietary supplements use.
Measured: From enrolment to the end of last measurement at 6 months.
LDL cholestorol
LDL cholesterol levels will be measured from venous blood at baseline, after 1, 3 and 6 months of daily dietary supplements use.
Measured: From enrolment to the end of last measurement at 6 months.
HDL cholesterol
HDL cholesterol levels will be measured from venous blood at baseline, after 1, 3 and 6 months of daily dietary supplements use.
Measured: From enrolment to the end of last measurement at 6 months.
Triacylglycerols
Triacylglycerols levels will be measured from venous blood at baseline, after 1, 3 and 6 months of daily dietary supplements use.
Measured: From enrolment to the end of last measurement at 6 months.
Antioxidant potential
Antioxidant potential will be measured from venous blood at baseline, after 1, 3 and 6 months of daily dietary supplements use.
Measured: From enrolment to the end of last measurement at 6 months.
Aspartate aminotransferase (AST)
AST will be measured from venous blood at baseline, after 1, 3 and 6 months of daily dietary supplements use.
Measured: From enrolment to the end of last measurement at 6 months.
Alanine aminotransferase (ALT)
ALT will be measured from venous blood at baseline, after 1, 3 and 6 months of daily dietary supplements use.
Measured: From enrolment to the end of last measurement at 6 months.
Interleukine-6 (IL-6)
IL-6 will be measured from venous blood at baseline, after 1, 3 and 6 months of daily dietary supplements use.
Measured: From enrolment to the end of last measurement at 6 months.
Tumor necrosis factor alpha (TNF-alpha)
TNF-alpha will be measured from venous blood at baseline, after 1, 3 and 6 months of daily dietary supplements use.
Measured: From enrolment to the end of last measurement at 6 months.
NAD+/NADH
NAD+/NADH ratio will be measured from venous blood at baseline and 6 months of daily dietary supplements use.
Measured: From enrolment to the end of last measurement at 6 months.
Sleep quality
Sleep quality will be assessed with The Pittsburgh Sleep Quality Index (PSQI) questionnaire (Buysse et al., 1989) at baseline, after 1, 3 and 6 months of daily dietary supplements use.
PSQI is a self-report questionnaire that evaluates sleep quality over the past month, using 19 items to generate 7 component scores (0-3 each) and a global score (0-21). A total global score >5 indicates poor sleep quality. Higher scores signify more severe sleep disturbances.
Measured: From enrolment to the end of last measurement at 6 months.
World Health Organization-FIve Well-Being Index
Quality of life will be assessed with World Health Organization-FIve Well-Being Index (WHO5 questionnaire, Slovenian translation, WHO, 2024) at baseline, after 1, 3 and 6 months of daily dietary supplements use.
The WHO-5 Well-Being Index is a 5-item self-report questionnaire measuring mental well-being over the past two weeks, scored on a 0-25 scale that is multiplied by 4 for a 0-100 range. Higher scores indicate better well-being, while a score 50 or less suggests poor well-being
Measured: From enrolment to the end of last measurement at 6 months.
BMAL1 gene expression
BMAL1 gene expression will be determined from Lymphocyte fraction at baseline and 6 months of daily dietary supplements use.
Measured: From enrolment to the end of last measurement at 6 months.
ATG1 gene expression
ATG1 gene expression will be determined from Lymphocyte fraction at baseline and 6 months of daily dietary supplements use.
Measured: From enrolment to the end of last measurement at 6 months.
SD1 gene expression
SD1 gene expression will be determined from Lymphocyte fraction at baseline and 6 months of daily dietary supplements use.
Measured: From enrolment to the end of last measurement at 6 months.
mTOR gene expression
mTOR gene expression will be determined from Lymphocyte fraction at baseline and 6 months of daily dietary supplements use.
Measured: From enrolment to the end of last measurement at 6 months.
SIRT1 gene expression
SIRT1 gene expression will be determined from Lymphocyte fraction at baseline and 6 months of daily dietary supplements use.
Measured: From enrolment to the end of last measurement at 6 months.
Glutation reductase gene expression
Glutation reductase gene expression will be determined from Lymphocyte fraction at baseline and 6 months of daily dietary supplements use.
Measured: From enrolment to the end of last measurement at 6 months.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Feb 2026
- Study start7 Mar 2026
- Primary completionOct 2026 (estimated)
- Study completionMar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for AgingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Double blind intervention study.
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Primorska
- Sponsor type
- University, hospital or other
- Collaborators
- Biostile
- Responsible party
- Principal investigator, Nina Mohorko, University of Primorska
- Investigators
- Ana Petelin, PhD, Principal investigator, University of Primorska, Faculty of Health Sciences
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07404449
- Sponsor's protocol ID
- DOLGOZIVOST
- Status last verified
- Feb 2026
- First submitted
- 4 Feb 2026
- Last updated
- 10 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Kyle UG, Bosaeus I, De Lorenzo AD, Deurenberg P, Elia M, Gomez JM, Heitmann BL, Kent-Smith L, Melchior JC, Pirlich M, Scharfetter H, Schols AM, Pichard C; Composition of the ESPEN Working Group. Bioelectrical impedance analysis--part I: review of principles and methods. Clin Nutr. 2004 Oct;23(5):1226-43. doi: 10.1016/j.clnu.2004.06.004.
PubMed 15380917Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193-213. doi: 10.1016/0165-1781(89)90047-4.
PubMed 2748771Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 2013;14(10):R115. doi: 10.1186/gb-2013-14-10-r115.
PubMed 24138928Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nat Rev Genet. 2018 Jun;19(6):371-384. doi: 10.1038/s41576-018-0004-3.
PubMed 29643443Ruan Z, Li D, Huang D, Liang M, Xu Y, Qiu Z, Chen X. Relationship between an ageing measure and chronic obstructive pulmonary disease, lung function: a cross-sectional study of NHANES, 2007-2010. BMJ Open. 2023 Nov 2;13(11):e076746. doi: 10.1136/bmjopen-2023-076746.
PubMed 37918922
Study at a glance
From the registry record, last updated by the sponsor on 10 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Sex-Speciffic Compound Food Supplements on Changes in Biomarkers and Epigenetic Changes Associated With Longevity
- ClinicalTrials.gov ID
- NCT07404449
- Acronym / sponsor ID
- DOLGOZIVOST
- Conditions
- Aging
- Keywords
- biological age, food supplement, longevity
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- University of PrimorskaUniversity, hospital or other
- Collaborators
- Biostile
- Study start
- 7 Mar 2026 (actual)
- Primary completion
- Oct 2026 (estimated)
- Study completion
- Mar 2027 (estimated)
- First posted
- 11 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The use of food supplements with the aim of increasing longevity in the general population is rapidly increasing, while high-quality clinical evidence on the efficacy of comprehensive formulations and their impact on biomarkers of aging is lacking. The investigators will perform a double-blind, placebo-controlled, randomized clinical trial of a selected sex-specific dietary supplement in relation to longevity in a selected population of healthy adults of both sexes between the ages of 50 and 70.
The main questions the study answers are:
Does the 6-month use of the longevity supplement impacts the 6-months change in different markers for measuring biological age compared to placebo?
The study will involve 60 subjects, of whom 30 will consume the sex-specific longevity food supplements and 30 will consume a placebo.
The study will last 6 months. The participants will visit the Faculty four times: at the beginning of the study (background measurement), after one, three and six months of consuming the dietary supplement or placebo.
At each visit, the participants will undergo anthropometric measurements, blood pressure measurements, and blood samples will be taken to determine baseline haematocrite, albumin, creatinine, alcaline phosphatase, lipid profile, glucose concentration, inflammatory parameters, antioxidant potential, inflammatory markers, liver enzymes, and expression of genes for autophagy and oxidative stress. The participants will also complete 3-day food diaries and questionnaires on general health, physical activity, and quality of sleep and life.
On baseline and final (six months) measurements resting metabolic rate, DXA body composition measurements will be performed and saliva samples will be obtained for DNA methilation determination.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 4
- Model description
- Double blind intervention study.
| Arm | Type | Receives |
|---|---|---|
| Female longevity food supplement | Experimental | Dietary Supplement: compound food supplements - female specific6-month daily consumption of 2 capsules of female food supplement in the morning. |
| Female placebo | Placebo comparator | Dietary Supplement: Placebo6-month daily consumption of 2 capsules of maltodextrin in the morning. |
| Male longevity food supplement | Experimental | Dietary Supplement: compound food supplements - male specific6-month daily consumption of 2 capsules of male food supplement in the morning. |
| Male placebo | Placebo comparator | Dietary Supplement: Placebo6-month daily consumption of 2 capsules of maltodextrin in the morning. |
Who may qualify
- Ages
- 50 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Body mass index (BMI) between 22 kg/m2 and 30 kg/m2
- Postmenopausal women (at least 12 months without menstruation)
- Healthy individuals, without risk of chronic non-communicable diseases
- Signed written informed consent
Key exclusion criteria (10 listed)
- Acute and chronic diseases (cardiovascular diseases, diabetes, neurodegenerative diseases, gastrointestinal diseases)
- Patients with serious clinical conditions such as cancer, severe infections, severe psychiatric disorders, autoimmune diseases, inflammatory diseases
- BMI less than 22 kg/m2 and greater than 30 kg/m2
- Celiac disease or gluten intolerance
- Presence of implants, devices or other foreign materials in the measurement area
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| compound food supplements - female specific2 capsules per day at breakfast with glass of water for 6 months. | Dietary supplement | Female longevity food supplement |
| compound food supplements - male specific2 capsules per day at breakfast with glass of water for 6 months. | Dietary supplement | Male longevity food supplement |
| Placebo2 capsules per day at breakfast with glass of water for 6 months. | Dietary supplement | Female placebo, Male placebo |
Primary outcome
Albumin
Time frame: From enrolment to the end of last measurement at 6 months.
Albumin levels will be measured from venous blood at baseline, after 1, 3 and 6 months of daily dietary supplements use.
Creatinine
Time frame: From enrolment to the end of last measurement at 6 months.
Creatinine levels will be measured from venous blood at baseline, after 1, 3 and 6 months of daily dietary supplements use.
Glucose
Time frame: From enrolment to the end of last measurement at 6 months.
Glucose levels will be measured from venous blood at baseline, after 1, 3 and 6 months of daily dietary supplements use.
CRP
Time frame: From enrolment to the end of last measurement at 6 months.
CRP levels will be measured from venous blood at baseline, after 1, 3 and 6 months of daily dietary supplements use.
Lymphocyte percent
Time frame: From enrolment to the end of last measurement at 6 months.
Lymphocyte percent will be measured from venous blood at baseline, after 1, 3 and 6 months of daily dietary supplements use.
Mean cell volume
Time frame: From enrolment to the end of last measurement at 6 months.
Mean cell volume will be measured from venous blood at baseline, after 1, 3 and 6 months of daily dietary supplements use.
Red cell distribution width
Time frame: From enrolment to the end of last measurement at 6 months.
Red cell distribution width will be measured from venous blood at baseline, after 1, 3 and 6 months of daily dietary supplements use.
Alcaline phosphatase
Time frame: From enrolment to the end of last measurement at 6 months.
Alcaline phosphatase will be measured from venous blood at baseline, after 1, 3 and 6 months of daily dietary supplements use.
White blood cell count
Time frame: From enrolment to the end of last measurement at 6 months.
White blood cell count will be measured from venous blood at baseline, after 1, 3 and 6 months of daily dietary supplements use.
PhenoAge
Time frame: From enrolment to the end of last measurement at 6 months.
PhenoAge will be calculated from albumin, creatinine, glucose, lymphocyte percent, mean cell volume, red cell distribution width, alcaline phosphatase, white blood cell count and cronological age at baseline, after 1, 3 and 6 months of daily dietary supplements use (according to Ruan et al, 2023).
DNA methylation
Time frame: From enrolment to the end of last measurement at 6 months.
DNA methylation will be measured from saliva at baseline and 6 months of daily dietary supplements use.
Horvath epigenetic age
Time frame: From enrolment to the end of last measurement at 6 months.
Horvath epigenetic age will be determined from saliva DNA methylation data (according to Horvath \& Raj, 2018) at baseline and 6 months of daily dietary supplements use..
18 secondary outcomes
Total cholesterol
Time frame: From enrolment to the end of last measurement at 6 months.
LDL cholestorol
Time frame: From enrolment to the end of last measurement at 6 months.
HDL cholesterol
Time frame: From enrolment to the end of last measurement at 6 months.
Triacylglycerols
Time frame: From enrolment to the end of last measurement at 6 months.
Antioxidant potential
Time frame: From enrolment to the end of last measurement at 6 months.
Aspartate aminotransferase (AST)
Time frame: From enrolment to the end of last measurement at 6 months.
Alanine aminotransferase (ALT)
Time frame: From enrolment to the end of last measurement at 6 months.
Interleukine-6 (IL-6)
Time frame: From enrolment to the end of last measurement at 6 months.
Tumor necrosis factor alpha (TNF-alpha)
Time frame: From enrolment to the end of last measurement at 6 months.
NAD+/NADH
Time frame: From enrolment to the end of last measurement at 6 months.
Sleep quality
Time frame: From enrolment to the end of last measurement at 6 months.
World Health Organization-FIve Well-Being Index
Time frame: From enrolment to the end of last measurement at 6 months.
BMAL1 gene expression
Time frame: From enrolment to the end of last measurement at 6 months.
ATG1 gene expression
Time frame: From enrolment to the end of last measurement at 6 months.
SD1 gene expression
Time frame: From enrolment to the end of last measurement at 6 months.
mTOR gene expression
Time frame: From enrolment to the end of last measurement at 6 months.
SIRT1 gene expression
Time frame: From enrolment to the end of last measurement at 6 months.
Glutation reductase gene expression
Time frame: From enrolment to the end of last measurement at 6 months.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Mar 2026.
- Background: PubMed 15380917Kyle UG, Bosaeus I, De Lorenzo AD, Deurenberg P, Elia M, Gomez JM, Heitmann BL, Kent-Smith L, Melchior JC, Pirlich M, Scharfetter H, Schols AM, Pichard C; Composition of the ESPEN Working Group. Bioelectrical impedance analysis--part I: review of principles and methods. Clin Nutr. 2004 Oct;23(5):1226-43. doi: 10.1016/j.clnu.2004.06.004.
- Background: PubMed 2748771Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193-213. doi: 10.1016/0165-1781(89)90047-4.
- Background: PubMed 24138928Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 2013;14(10):R115. doi: 10.1186/gb-2013-14-10-r115.
- Background: PubMed 29643443Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nat Rev Genet. 2018 Jun;19(6):371-384. doi: 10.1038/s41576-018-0004-3.
- Background: PubMed 37918922Ruan Z, Li D, Huang D, Liang M, Xu Y, Qiu Z, Chen X. Relationship between an ageing measure and chronic obstructive pulmonary disease, lung function: a cross-sectional study of NHANES, 2007-2010. BMJ Open. 2023 Nov 2;13(11):e076746. doi: 10.1136/bmjopen-2023-076746.
- WHO5 Slovenian translationLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Aging
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
RecruitingObservational study
Amyloid PET Imaging in the Baltimore Longitudinal Study of Aging
Aging
RecruitingPhase 4
PLLA and CaHA-R for Aesthetic Rejuvenation
Aesthetic
RecruitingObservational study
Genetic and Epigenetic Signatures of Translational Aging Laboratory Testing (GESTALT)
Healthy Volunteers, Non-Healthy/Non-Frail
Recruiting
Exercise for an Aging Liver (EXALIVER)
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ana Petelin, PhD principal investigator
University of Primorska, Faculty of Health Sciences
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing compound food supplements - female specific and compound food supplements - male specific in people with Aging, run by University of Primorska at 1 site in Slovenia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 10 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Slovenia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Albumin (time frame: From enrolment to the end of last measurement at 6 months.). The study lists 12 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07404449, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Mar 2026.